Epidemiology and Carcinogenesis of Rectal Cancer

  • Jai Bikhchandani
  • Alan G. Thorson
  • Henry T. Lynch
Chapter

Abstract

Cancer of the colon and rectum is extremely common in the Western hemisphere. The etiopathogenesis of colorectal cancer is an intertwined play of several genetic and environmental factors to which an individual is exposed to during the lifetime. The predominance of one factor over another decides the timing of development of this cancer with respect to the individual’s age. Familial syndromes like Lynch syndrome and familial adenomatous polyposis predispose an individual to cancer early in their lifespan since they carry the genetic mutation. A sporadic cancer, on the other hand, follows a very interesting and often predictable path from a polyp to carcinoma. There are three such pathways which the colonic epithelium may undertake toward the development of cancer. Each of the pathways has its own unique set of genotypic and phenotypic expression which needs to be understood well to accomplish our ultimate goal for prevention of colorectal cancer.

Keywords

Colorectal cancer Epidemiology Lynch syndrome Carcinogenesis Polyp-carcinoma sequence 

Notes

Acknowledgments

This work was supported by revenue from Nebraska cigarette taxes awarded to Creighton University by the Nebraska Department of Health and Human Services. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the State of Nebraska or the Nebraska Department of Health and Human Services.

References

  1. 1.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. CA Cancer J Clin. 2009;59:225–49.CrossRefPubMedGoogle Scholar
  2. 2.
    Boyle P, Langman JS. ABC of colorectal cancer: epidemiology. BMJ. 2000;321:805–8.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Wingo PA, Cardinez CJ, Landis SH, Greenlee RT, Ries LA, Anderson RN, et al. Long-term trends in cancer mortality in the United States, 1930–1998. Cancer. 2003;97:3133–275.CrossRefPubMedGoogle Scholar
  4. 4.
    American Cancer Society Website Cancer Facts and Figures. http://www.cancer.org/downloads/STT/500809web.pdf. Accessed 16 Dec 2009.
  5. 5.
    O’Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, Ko CY. Rates of colon and rectal cancers are increasing in young adults. Am Surg. 2003;69:866–72.PubMedGoogle Scholar
  6. 6.
    Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin. 2002;52:23–47. [Erratum, CA Cancer J Clin 2002;52:119, 181-2]CrossRefPubMedGoogle Scholar
  7. 7.
    Eide TJ. Natural history of adenomas. World J Surg. 1991;15:3–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525–32.CrossRefPubMedGoogle Scholar
  9. 9.
    Kronborg O, Fenger C. Clinical evidence of the adenoma–carcinoma sequence. Eur J Cancer Prev. 1999;8:573–86.CrossRefGoogle Scholar
  10. 10.
    Jackman RJ, Mayo CW. The adenoma-carcinoma sequence in cancer of the colon. Surg Gynecol Obstet. 1951;93:327–30.PubMedGoogle Scholar
  11. 11.
    Church JM, Williams BR, Casey G. Molecular genetics and colorectal neo- plasia. In: A primer for the clinician. New York: Igaku-Shoin Medical Publishers; 1996.Google Scholar
  12. 12.
    Arends MJ. Pathways of colorectal carcinogenesis. Appl Immunohistochem Mol Morphol. 2013;21(2):97–102.PubMedGoogle Scholar
  13. 13.
    Goldstein NS. Serrated pathway and APC (conventional)-type colorectal polyps: molecular-morphologic correlations, genetic pathways, and implications for classification. Am J Clin Pathol. 2006;125:146–53.CrossRefPubMedGoogle Scholar
  14. 14.
    Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA. Kirsten ras mutations in patients with colorectal cancer: the multicenter “RASCAL” study. J Natl Cancer Inst. 1998;90:675–84.CrossRefPubMedGoogle Scholar
  15. 15.
    Naguib A, Wilson CH, Adams DJ, Arends MJ. Activation of K-RAS by co- mutation of codons 19 and 20 is transforming. J Mol Signal. 2011;6:2.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757–65.CrossRefPubMedGoogle Scholar
  17. 17.
    Gordon PH. Malignant neoplasms of the colon. In: Gordon PH, Nivatvongs S, editors. Principles and practice of surgery for the colon, rectum and anus. 3rd ed. New York, London: Informa Healthcare; 2007. p. 489–643.Google Scholar
  18. 18.
    Rosati G, Chiacchio R, Reggiardo G, De Sanctis D, Manzione L. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival. Tumor Biol. 2004;25:258–63.CrossRefGoogle Scholar
  19. 19.
    Resnick MB, Routhier J, Konkin T, Sabo E, Pricolo VE. Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin Cancer Res. 2004;10:3069–75.CrossRefPubMedGoogle Scholar
  20. 20.
    Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348:919–32.CrossRefPubMedGoogle Scholar
  21. 21.
    Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP, et al. Clues to the pathogenesis of familial colorectal cancer. Science. 1993;260:812–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Longacre TA, Fenoglio-Preiser CM. Mixed hyperplastic adenomatous polyps serrated adenomas. A distinct form of colorectal neoplasia. Am J Surg Pathol. 1990;14:524–37.CrossRefPubMedGoogle Scholar
  23. 23.
    Baker K, Zhang Y, Jin C, Jass JR. Proximal versus distal hyper- plastic polyps of the colorectum: different lesions or a biological spectrum? J Clin Pathol. 2004;57:1089–93.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Jass JR. Hyperplastic polyps and colorectal cancer: is there a link? Clin Gastroenterol Hepatol. 2004;2:1–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Bettington M, Walker N, Clouston A, Brown I, Leggett B, Whitehall V. The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology. 2013;62:367–86.CrossRefPubMedGoogle Scholar
  26. 26.
    Grady WM, Markowitz SD. The molecular pathogenesis of colorectal cancer and its potential application to colorectal cancer screening. Dig Dis Sci. 2015;60:762–72.CrossRefPubMedGoogle Scholar
  27. 27.
    Lynch HT, Smyrk T, McGinn T, Lanspa S, Cavelieri J, Lynch J, et al. Attenuated familial adenomatous polyposis (AFAP). A phenotypically and genotypically distinct variant of FAP. Cancer. 1995;76:2427–33.CrossRefPubMedGoogle Scholar
  28. 28.
    Bulow S. The Danish polyposis registry. Dis Colon Rectum. 1984;27:351–5.CrossRefPubMedGoogle Scholar
  29. 29.
    Watson P, Lynch HT. The tumor spectrum in HNPCC. Anticancer Res. 1994;14:1635–9.PubMedGoogle Scholar
  30. 30.
    Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med. 2000;342:69–77.CrossRefPubMedGoogle Scholar
  31. 31.
    Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. New York: McGraw-Hill; 1998.Google Scholar
  32. 32.
    Smyrk TC, Watson P, Kaul K, Lynch HT. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer. 2001;91:2417–22.CrossRefPubMedGoogle Scholar
  33. 33.
    Alexander J, Watanabe T, Wu T-T, Rashid A, Li S, Hamilton SR. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol. 2001;158:527–351998.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Jass JR, Do K-A, Simms LA, Lino H, Wynter C, Pillay SP, et al. Morphology of sporadic colorectal cancer with DNA replication errors. Gut. 1998;42:673–9.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Jass JR, Stewart SM. Evolution of hereditary non-polyposis colorectal cancer. Gut. 1992;33:783–6.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Peltomaki P, Lothe RA, Aaltonen LA, Pylkkanen L, Nystrom-Lahti M, Seruca R, et al. Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome. Cancer Res. 1993;53:5853–5.PubMedGoogle Scholar
  37. 37.
    Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58:5248–57.PubMedGoogle Scholar
  38. 38.
    Cunningham C, Dunlop MG. Molecular genetic basis of colorectal cancer sus- ceptibility. Br J Surg. 1996;83:321–9.CrossRefPubMedGoogle Scholar
  39. 39.
    Burkitt DP. Related disease–related cause? Lancet. 1969;2:1229–31.CrossRefPubMedGoogle Scholar
  40. 40.
    Nagao M, Sugimura T. Carcinogenic factors in food with relevance to colon. cancer development. Mutat Res. 1993;290:43–51.CrossRefPubMedGoogle Scholar
  41. 41.
    Jain M, Cook GM, Davis FG, Grace MG, Howe GR, Miller AB. A case-control study of diet and colorectal cancer. Int J Cancer. 1980;26:757–68.CrossRefPubMedGoogle Scholar
  42. 42.
    Potter JD, McMichael AJ. Diet and cancer of the colon and rectum: a case- control study. J Natl Cancer Inst. 1986;76:557–69.CrossRefPubMedGoogle Scholar
  43. 43.
    Phillips RL, Snowdon DA. Dietary relationships with fatal colorectal cancer among seventh-day Adventists. J Natl Cancer Inst. 1985;74:307–17.PubMedGoogle Scholar
  44. 44.
    Garland C, Shekelle RD, Barrett-Connor E, Criqui MH, Rossof AH, Paul O. Dietary vitamin D and calcium and risk of colorectal cancer: a 19 year prospective study in men. Lancet. 1985;1:307–9.CrossRefPubMedGoogle Scholar
  45. 45.
    Fleiszer D, Murray D, MacFarlane J, Brown RA. Protective effect of dietary fiber against chemically induced bowel tumors in rats. Lancet. 1978;2:552–3.CrossRefPubMedGoogle Scholar
  46. 46.
    Greenwald P, Lanza E, Eddy GA. Dietary fiber in the reduction of colon cancer. J Am Diet Assoc. 1987;87:1178–88.PubMedGoogle Scholar
  47. 47.
    Trock B, Lanza E, Greenwald P. Dietary fiber, vegetables and colon cancer: critical review and meta-analysis of the epidemiological evidence. J Natl Cancer Inst. 1990;82:650–61.CrossRefPubMedGoogle Scholar
  48. 48.
    Asano T, McLeod RS. Dietary fiber for the prevention of colorectal adenomas and carcinomas. Cochrane Database Syst Rev. 2002;2:CD003430.Google Scholar
  49. 49.
    Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Stampfer MJ, Rosner B, et al. Dietary fiber and the risk of colorectal cancer and adenoma in women. N Engl J Med. 1999;340:169–76.CrossRefPubMedGoogle Scholar
  50. 50.
    Willett WC, Stampfer MJ, Colditz GA, Rosner BA, Speizer FE. Relation of meat, food, and fiber intake to the risk of colon cancer in a prospective study amongst women. N Engl J Med. 1990;323:1664–72.CrossRefPubMedGoogle Scholar
  51. 51.
    Howe GR, Aronson KJ, Benito E, Castelleto R, Cornee J, Duffy S, et al. The relationship between dietary fat intake and risk of colorectal cancer: evidence from the combined analysis of 13 case-control studies. Cancer Causes Control. 1997;8:215–28.CrossRefPubMedGoogle Scholar
  52. 52.
    Beresford SA, Johnson KC, Ritenbaugh C, Lasser NL, Snetselaar LG, Black HR, et al. Low-fat dietary pattern and risk of colorectal cancer: the Women’s health initiative randomized controlled dietary modification trial. JAMA. 2006;295:643–54.CrossRefPubMedGoogle Scholar
  53. 53.
    Larsson SC, Rafter J, Holmberg L, Bergvist L, Wolk A. Red meat consumption and risk of cancers of the proximal colon, distal colon and rectum: the Swedish mammography cohort. Int J Cancer. 2005;113:829–34.CrossRefPubMedGoogle Scholar
  54. 54.
    Norat T, Bingham S, Ferrari P, Slimani N, Jenab M, Mazuir M, Overvad K, et al. Meat, fish, and colorectal cancer risk: the European prospective investigation into cancer and nutrition. J Natl Cancer Inst. 2005;97:906–16.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Peters U, Sinha R, Chatterjee N, Subar AF, Ziegler RG, Kulldorff M, et al. Dietary fibre and colorectal adenoma in a colorectal cancer early detection program. Lancet. 2003;361:1491–5.CrossRefPubMedGoogle Scholar
  56. 56.
    Lognecker MP. A case-control study of alcoholic beverage consumption in relation to risk of cancer of the right colon and rectum in men. Cancer Causes Control. 1990;1:5–14.CrossRefGoogle Scholar
  57. 57.
    Sharpe CR, Siemiatycki J, Rachet B. Effects of alcohol consumption on the risk of colorectal cancer among men by anatomical subsite (Canada). Cancer Causes Control. 2002;13:483–91.CrossRefPubMedGoogle Scholar
  58. 58.
    Correa P, Haenszel W. The epidemiology of large bowel cancer. Adv Cancer Res. 1978;26:1–141.CrossRefPubMedGoogle Scholar
  59. 59.
    Kikendall JW, Bowen PE, Burgess MB, Magnetti C, Woodward J, Langenberg P, et al. Cigarettes and alcohol as independent risk factors for colonic adenomas. Gastroenterology. 1989;97:660–4.CrossRefPubMedGoogle Scholar
  60. 60.
    Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Kearney J, et al. A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in U.S. men. J Natl Cancer Inst. 1994;86:183–91.CrossRefPubMedGoogle Scholar
  61. 61.
    Giovannucci E, Colditz GA, Stampfer MJ, Hunter D, Rosner BA, Willett WC, et al. A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in U.S. women. J Natl Cancer Inst. 1994;86:192–9.CrossRefPubMedGoogle Scholar
  62. 62.
    Lin J, Zhang SM, Cook NR, Rexrode KM, Lee IM, Buring JE. Body mass index and risk of colorectal cancer in women (United States). Cancer Causes Control. 2004;15:581–9.CrossRefPubMedGoogle Scholar
  63. 63.
    Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer Incidence and mortality in relation to body mass index in the million women study: cohort study. BMJ. 2007;335:1134.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Sturmer T, Buring JE, Lee IM, Gaziano JM, Glynn RJ. Metabolic abnormalities and risk for colorectal cancer in the physicians’ health study. Cancer Epidemiol Biomarkers Prev. 2006;15:2391–7.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Larsson SC, Wolk A. Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr. 2007;86:556–65.PubMedGoogle Scholar
  66. 66.
    Samad AK, Taylor RS, Marshall T, Chapman MA. A meta-analysis of the association of physical activity with reduced risk of colorectal cancer. Colorectal Dis. 2005;7:204–13.CrossRefPubMedGoogle Scholar
  67. 67.
    Howard RA, Freedman DM, Park Y, Hollenbeck A, Schatzkin A, Leitzmann MF. Physical activity, sedentary behavior, and the risk of colon and rectal cancer in the NIH-AARP diet and health study. Cancer Causes Control. 2008;19:939–53.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Harriss DJ, Atkinson G, Batterham A, George K, Cable NT, Reilly T, et al. Lifestyle factors and colorectal cancer risk (2): a systematic review and meta- analysis of associations with leisure-time physical activity. Colorectal Dis. 2009;11:689–701.CrossRefPubMedGoogle Scholar
  69. 69.
    Hawk ET, Umar A, Viner JL. Colorectal cancer chemoprevention – an overview of the science. Gastroenterology. 2004;126:1423–47.CrossRefPubMedGoogle Scholar
  70. 70.
    Asano TK, McLeod RS. Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas. Cochrane Database Syst Rev. 2004;(2):CD004079.Google Scholar
  71. 71.
    Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst. 1993;85:1220–4.CrossRefPubMedGoogle Scholar
  72. 72.
    Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348:891–9.CrossRefPubMedGoogle Scholar
  73. 73.
    Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348:883–90.CrossRefPubMedGoogle Scholar
  74. 74.
    Benamouzig R, Deyra J, Martin A, Girard B, Jullian E, Piednoir B, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology. 2003;125:328–36.CrossRefPubMedGoogle Scholar
  75. 75.
    Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, et al. Treatment of colonic and rectal adenomas with sulindac in familial ade- nomatous polyposis. N Engl J Med. 1993;328:1313–6.CrossRefPubMedGoogle Scholar
  76. 76.
    Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, Trimbath JD, et al. Primary chemo- prevention of familial adenomatous polyposis with sulindac. N Engl J Med. 2002;346:1054–9.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, et al. Sulindac causes regres- sion of rectal polyps in familial adenomatous polyposis. Gastroenterology. 1991;101:635–9.CrossRefPubMedGoogle Scholar
  78. 78.
    Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946–52.CrossRefPubMedGoogle Scholar
  79. 79.
    Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomized and observational studies. Lancet. 2007;369:1603–13.CrossRefPubMedGoogle Scholar
  80. 80.
    Logan RF, Grainge MJ, Shepherd VC, Armitage NC, Muir KR. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology. 2008;134:29–38.CrossRefPubMedGoogle Scholar
  81. 81.
    Suleiman S, Rex DK, Sonnenberg A. Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis. Gastroenterology. 2002;122:78–84.CrossRefPubMedGoogle Scholar
  82. 82.
    Hur C, Simon LS, Gazelle GS. The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individuals. Cancer. 2004;101:189–97.CrossRefPubMedGoogle Scholar
  83. 83.
    Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526–35.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323:1228–33.CrossRefPubMedGoogle Scholar
  85. 85.
    Oetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002;56:48–54.CrossRefGoogle Scholar
  86. 86.
    Collins PD, Mpofu C, Watson AJ, Rhodes JM. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev. 2006;(2):CD000279.Google Scholar
  87. 87.
    Gillen CD, Walmsley RS, Prior P, Andrews HA, Allan RN. Ulcerative colitis and Crohns disease: a comparison of the colorectal cancer risk in extensive colitis. Gut. 1994;35:1590–2.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Japan 2018

Authors and Affiliations

  • Jai Bikhchandani
    • 1
  • Alan G. Thorson
    • 2
  • Henry T. Lynch
    • 1
  1. 1.Department of Preventive MedicineCreighton UniversityOmahaUSA
  2. 2.Colon and Rectal Surgery Inc.OmahaUSA

Personalised recommendations